EVis Bioscience develops a proprietary EVis NanoVector platform to efficiently load RNA into extracellular vesicles (EVs) as a next-generation RNA delivery system. The company positions EVs as a natural delivery system with potential advantages in precision, safety, and scalability. EVis pursues a hybrid business model that includes platform licensing, R&D collaborations with industry and academia, and advancing its own therapeutic candidates for rare genetic diseases toward preclinical milestones. It has secured both grant funding (a CHF 311,000 Innosuisse award for a collaborative preclinical program with the University of Zurich) and equity via a €740,000 pre-seed round closed on Capital Cell. The company says it will use the new funds to expand its scientific team, strengthen preclinical programs, and prepare for future strategic financing rounds.

Total raised

$1M

Funding rounds

1

Latest round

Seed

Latest activity

Mar 2026